• LAST PRICE
    152.7100
  • TODAY'S CHANGE (%)
    Trending Down-3.4600 (-2.2155%)
  • Bid / Lots
    140.0000/ 1
  • Ask / Lots
    171.0000/ 1
  • Open / Previous Close
    154.3800 / 156.1700
  • Day Range
    Low 152.0200
    High 156.3500
  • 52 Week Range
    Low 126.9681
    High 241.5000
  • Volume
    144,597
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 156.17
TimeVolumeBGNE
09:32 ET2403152.81
09:34 ET1900152.66
09:36 ET713153.99
09:38 ET200153.53
09:39 ET100155.31
09:41 ET1050154.12
09:43 ET100155.705
09:45 ET2886155.09
09:48 ET1900155.63
09:50 ET200155.505
09:52 ET200155.98
09:57 ET400155.51
09:59 ET100155.52
10:03 ET100155.81
10:06 ET6550155.67
10:08 ET600155.8
10:12 ET100155.77
10:14 ET200155.72
10:15 ET1590155.67
10:17 ET6860155.77
10:19 ET100155.325
10:21 ET2000154.6997
10:24 ET200154.7
10:26 ET200154.5
10:28 ET100154.1675
10:30 ET100154.17
10:32 ET200153.92
10:33 ET100154.395
10:35 ET217153.87
10:46 ET200153.89
10:48 ET200154.32
10:50 ET200154.05
10:51 ET200154.1661
10:53 ET100154.5
10:55 ET415153.95
10:57 ET300154.47
11:02 ET100154.21
11:04 ET400154.03
11:08 ET100154.45
11:11 ET399154.195
11:15 ET200154.49
11:18 ET300154.04
11:20 ET1373153.88
11:22 ET100153.96
11:26 ET200154.1
11:29 ET400154.225
11:40 ET400154.135
11:42 ET200154.13
11:56 ET100154.005
11:58 ET100154.18
12:03 ET100154.22
12:12 ET276154.11
12:27 ET200154.5
12:38 ET200154.74
12:41 ET100154.84
12:43 ET1090154.94
12:45 ET100155.19
12:48 ET100155.2
12:50 ET415155.15
12:52 ET104155.03
12:54 ET203155.0961
12:56 ET100155.18
12:57 ET600154.85
12:59 ET100154.9
01:06 ET604154.635
01:10 ET300154.44
01:12 ET1300154.67
01:14 ET495154.86
01:15 ET100154.845
01:17 ET100154.815
01:19 ET100154.53
01:21 ET400154.66
01:24 ET1804154.04
01:28 ET100154.03
01:30 ET288154.04
01:35 ET300153.8
01:37 ET100153.78
01:39 ET300153.66
01:42 ET400153.34
01:44 ET1113153.755
01:50 ET100153.735
01:51 ET100153.42
01:53 ET1497153.79
01:55 ET450153.72
01:57 ET388153.4509
02:00 ET100153.24
02:04 ET627153.36
02:09 ET500153.15
02:11 ET100153.15
02:13 ET100152.7
02:15 ET100152.5
02:18 ET150152.5
02:20 ET300152.77
02:22 ET100152.8
02:29 ET400152.42
02:31 ET100152.855
02:33 ET105152.56
02:36 ET100152.97
02:40 ET100152.52
02:42 ET737153.15
02:44 ET147152.5
02:45 ET118152.515
02:47 ET200152.49
02:54 ET100152.52
02:56 ET300152.36
03:02 ET100152.57
03:09 ET200152.37
03:12 ET596152.69
03:14 ET100152.9
03:21 ET320152.72
03:27 ET432152.7
03:32 ET100152.51
03:38 ET825152.39
03:39 ET100152.02
03:41 ET366152.27
03:43 ET115152.06
03:45 ET352152.345
03:48 ET722152.53
03:50 ET317152.46
03:52 ET650152.47
03:54 ET1563152.65
03:56 ET2540152.745
03:57 ET1631152.8
03:59 ET1100152.71
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBGNE
Beigene Ltd
16.5B
-20.2x
---
United StatesBMRN
Biomarin Pharmaceutical Inc
14.3B
71.5x
---
United StatesUTHR
United Therapeutics Corp
12.1B
12.9x
+8.22%
United StatesNBIX
Neurocrine Biosciences Inc
14.0B
38.3x
+62.04%
United StatesALNY
Alnylam Pharmaceuticals Inc
18.7B
-54.5x
---
United StatesEXAS
Exact Sciences Corp
9.2B
-37.6x
---
As of 2024-05-25

Company Information

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Contact Information

Headquarters
94 Solaris Avenue,, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
Phone
345-949-4123
Fax
---

Executives

Co-Founder, Executive Chairman of the Board, Chief Executive Officer
John Oyler
President, Chief Operating Officer, General Manager - China
Xiaobin Wu
Co-Founder, Non-Executive Director
Xiaodong Wang
Chief Financial Officer
Julia Wang
Global Head of R&D
Lai Wang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$16.5B
Revenue (TTM)
$2.8B
Shares Outstanding
104.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.61
EPS
$-7.57
Book Value
$36.95
P/E Ratio
-20.2x
Price/Sales (TTM)
6.0
Price/Cash Flow (TTM)
---
Operating Margin
-26.60%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.